Trial Profile
Phase 2, single arm study of ticilimumab in patients with refractory metastatic adenocarcinoma of the colon or rectum
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Tremelimumab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 06 Jun 2012 Company (AstraZeneca) added as reported by ClinicalTrials.gov.
- 10 Jul 2008 Status changed from in progress to completed, from clinicaltrials.gov record.
- 06 Nov 2006 New trial record.